

# Introduction to Regulatory Affairs and Different Regulatory Bodies for Pharmaceutical Products and Impact of Digitalization on Regulatory Affairs

Tanzeel Huma\*, Zhou Peng

Beijing Yisheng Biotechnology Co., Ltd., Beijing, China

Email: \*tanzeelhuma@gmail.com

**How to cite this paper:** Huma, T. and Peng, Z. (2023) Introduction to Regulatory Affairs and Different Regulatory Bodies for Pharmaceutical Products and Impact of Digitalization on Regulatory Affairs. *Pharmacology & Pharmacy*, 14, 463-477. <https://doi.org/10.4236/pp.2023.1411030>

**Received:** October 18, 2023

**Accepted:** November 25, 2023

**Published:** November 28, 2023

Copyright © 2023 by author(s) and Scientific Research Publishing Inc.

This work is licensed under the Creative Commons Attribution-NonCommercial International License (CC BY-NC 4.0).

<http://creativecommons.org/licenses/by-nc/4.0/>



Open Access

---

## Abstract

To ensure the quality and marketability of products, the field of regulatory affairs (RA) serves as an intermediary between regulatory bodies, the industry, and consumers. The primary objective of pharmaceutical registration is centered on the marketing process. The World Health Organization (WHO), Pan American Health Organization (PAHO), World Trade Organization (WTO), International Conference on Harmonization (ICH), and World Intellectual Property Organization (WIPO) play crucial roles in the process. Drug registration and commercialization are overseen by national regulatory authorities initially, following the guidelines of the key organizations. The phenomenon of digital disruption is widespread and has significant effects on several domains of work. This influence has been further intensified by the COVID-19 epidemic, as well as the rapid advancements in the complexity and capabilities of machine learning and artificial intelligence algorithms. The future of this profession is influenced by various trends, including the swift progress in scientific comprehension of diseases, which has resulted in the emergence of novel therapeutic approaches for the treatment and potential eradication of some ailments. The importance of strategic collaborations, alignment, and integration among national regulatory agencies has been heightened by recent global regulatory reforms. This trend is expected to persist. The impact of these elements on regulatory professionals, medication development, and medical practice in the future is a subject of considerable attention. The enhancement of skills and the adoption of a growth mindset are crucial for regulatory affairs professionals to implement the necessary adjustments. This emerging paradigm promotes the cultivation of personal responsibility in individuals' professional development, fostering adaptability and emphasizing the significance of lifelong learning. Through their actions,

---

these specialists could exert influence on the process of product development, contributing to the improvement of their society.

### **Keywords**

Drug Regulatory Authorities, Future Trends, Centralization of the Regulatory Authorities

---

## **1. Introduction**

The regulatory affairs (RA) field is concerned with the regulatory requirements for pharmaceutical product marketing authorization. Regulatory affairs professionals mediate the interaction between regulators (the government), the regulated [industry], and the market (consumers) to get good products to market and maintain them there while preventing poor quality and efficacy products from being sold. On the industry side, regulatory affairs professionals collaborate with research scientists, physicians, manufacturing organizations, and sales and marketing teams to ensure that the government gets the information it requires to evaluate a product. People in regulatory affairs work for the government to interpret and enforce laws passed by Congress to safeguard the public. People in regulatory affairs help keep the other two groups honest, and they provide the impetus for Congress to pass rules that control how the government and industry treat products. Basically, RA acts as an intermediary between the pharmaceutical sector and drug regulatory authorities globally. It primarily focuses on the registration of pharmaceutical goods in their various nations prior to marketing.

Recently, there has been a rise in the involvement of patients in all areas of drug development, including regulatory review, which has impacted medical product regulation [1]. Because of speedier clinical trials, drugs will be able to reach the market at an earlier stage of development, leading regulators to lay a larger emphasis on post-market oversight. To increase efficiencies at this level of development, the clinical trial business is incorporating more modeling, newer statistical methodology, and artificial intelligence [2] [3]. Furthermore, regulatory agencies are collaborating more and adopting work-sharing, dependence, and cooperative reviews to facilitate the review of these novel items entering the regulatory system [4] [5]. All of these developments necessitate a workforce that is adaptable, technologically proficient, and capable of learning and adapting work practices to suit these new trends. This article will look at the many factors influencing the development of novel therapies for disease relief and how these developments affect the function of the regulatory bodies and regulatory affairs professional.

## **2. Key Regulatory Agencies**

Some of the international regulatory agencies and organizations that play an

important role in all aspects of pharmaceutical regulations include the World Health Organization (WHO), Pan American Health Organization (PAHO), World Trade Organization (WTO), International Conference on Harmonization (ICH), and World Intellectual Property Organization (WIPO).

The key problems for these regulatory authorities and organizations worldwide are to ensure the safety, quality, and efficacy of medicines and medical devices, to harmonize legislative procedures connected to drug development, and to monitor and ensure compliance with statutory requirements. They also play an important role in ensuring and increasing regulatory implementation in non-regulated areas of the world to protect the safety of those who live there.

The major challenges for these regulatory bodies are: 1) Promoting public health and protecting the public from harmful and dubious drugs; and 2) Establishing proper legalization covering all products with a medicinal claim and all relevant pharmaceutical activities, whether carried out by the public or private sector. 3) Increase global regulatory growth to ensure people's safety. 4) Centralization of the regulatory process and control.

### 3. National Regulatory Bodies

The regulatory body ensures compliances in various legal and regulatory aspects of a drug. Each country has its own regulatory body which controls the registration and marketing of the medicinal products at the national level. That national level regulatory body governs the rules and regulations. Additionally, it issues the guidelines for the drug development, licensing, registration, manufacturing, marketing, and labelling of the pharmaceutical products. USFDA (USA), MHRA (UK), TGA (Australia), CDSCO (India), DRAP (Pakistan) HEALTH CANADA (CANADA), MCC (South Africa), ANVISA (Brazil), EMEA (European Union), NMPA (China), NAFDAC (Nigeria), MEDSAFE (New Zealand), MHLW (Japan), HAS (SINGAPORE) MCAZ (Zimbabwe), SWISSMEDIC (Switzerland), KFDA (Korea), are the few regulatory agencies and organizations established in respective countries [6].

### 4. Key Trends and Global Problems

Getting the better understanding of the sole global trends can positively help the regulatory affairs professionals to predict the future impact on their role and responsibilities. Recently, the key global trends have been updated by the (CSIRO) Commonwealth Scientific and Industrial Research Organization, and enlisted adapting to changing environment, diving into digital dimension cleaner and greener, increasingly autonomous, unlocking the health imperative, and unlocking the human [7]. Such major developments have the potential to influence the future of medicine, therapeutic product development, and the way regulatory professionals do their work. Concerns about climate change are influencing manufacturing, with an emphasis on sustainable methods, reduced environmental effect, and a shift towards a circular industrial economy [8]. The increased push

by countries to manufacture vital pharmaceutical items locally, in response to the COVID-19 pandemic, reflects geopolitical instability [9]. The COVID-19 pandemic has emphasized the dangers of infectious diseases, which are expected to worsen because of climate change. Antimicrobial resistance, an ageing population's growing chronic health burden, increased pressures on mental health, and budget limits on healthcare spending will all have an impact on the pharmaceutical industry. More optimistically, the prospect of precision medicine, more digital connectivity across the healthcare system, a shift towards a learning healthcare system, and an emphasis on wellbeing and preventative medicine will lead to future healthcare advancements as well as possibilities for industry [10] [11] [12]. The evolution of harmonization, convergence, and reliance has led to the establishment of a work-sharing arrangement known as the ACCESS Consortium. This arrangement involves comparable, mid-sized national regulatory authorities from Australia, Canada, Singapore, Switzerland, and the United Kingdom. Additionally, these countries are active partners in Project ORBIS. The practice of work sharing has evolved over time through the establishment of robust information sharing mechanisms and the cultivation of trust among participating regulatory bodies. This has led to a system where these regulatory authorities divide the review of Modules, while adhering to confidentiality agreements and memorandum of understanding that have been mutually agreed upon. Each participant maintains their individual autonomy in decision-making; however, the process alleviates the burden on regulators and facilitates the exchange of expertise across various geographical regions.

## 5. Digital Disruption

The drug development process is increasingly being affected by digital disruption, which encompasses several stages such as early-stage discovery and validation of target molecules, optimization of candidate drug structure, manufacturing processes, and regulatory clearances by national regulatory bodies.

One of the primary difficulties encountered in the initial phases of drug development is the determination of the structure of target proteins, followed by the identification and optimization of suitable drug candidates capable of interacting with these proteins to impede or modify their functionality.

Artificial intelligence (AI) and machine learning (ML) are becoming a progressively significant role in the field of drug discovery [13]. The implementation of their application is expected to decrease the incidence of failure in the initial stages of drug research and development, while also expediting this phase in the overall process [14] [15] [16]. Additionally, it is expected to mitigate the potential hazards and financial burdens associated with the process of pharmaceutical development. Alphabet's DeepMind AI demonstrated remarkable success in predicting the three-dimensional (3D) structure of many proteins during the biennial Critical Assessment of Structure Prediction (CASP) competition in both 2018 and 2020 [17]. Subsequently, DeepMind has made available an open-source AlphaFold protein structure database, which may be utilized by research-

ers and pharmaceutical developers to ascertain the three-dimensional configuration of prospective targets for the purpose of medication development [14]. In recent times, there has been an increased application of AI/ML systems, such as PandaOmics and Chemistry42, in the field of scientific research. These systems have been employed not only for the purpose of discovering new targets but also for speeding up identifying lead candidate molecules [15] [16]. To enhance trust in the use of AI/ML, it is imperative to build robust governance structures and ethical frameworks. Additionally, organizations that heavily rely on these systems must have well-defined quality assurance and auditing methods. Regulatory professionals must possess a high level of confidence in effectively communicating the intricacies of these technologies, guaranteeing their adherence to governmental regulations, and collaborating with regulatory authorities during the registration process of medicinal goods based on artificial intelligence and machine learning. Organizations must possess the capability to incorporate these systems into their established benefit-risk decision-making procedures and effectively convey this integration both internally and externally to relevant stakeholders.

Digital twins refer to virtual representations of physical assets or processes that possess the ability to accurately duplicate the behavior shown by the corresponding genuine asset or process [18]. The utilization of digital twins has the potential to enhance the efficiency of pharmaceutical manufacturing. This is achieved through the simulation of process flows prior to their implementation, which allows for the optimization of these processes. Additionally, digital twins facilitate technology transfer by enabling the testing of new manufacturing plants before their physical construction. Furthermore, personnel can receive training within the digital twin environment, preparing them for their roles within the actual manufacturing plant [18] [19]. Pharmaceutical corporations, such as GSK, have previously employed digital twin models to enhance the efficiency of their vaccine development and production procedures [20].

An additional use of digital twins involves the simulation of disease progression. This advancement is expected to result in the establishment of digital twin control groups for use in clinical trials, therefore mitigating ethical and operational issues associated with traditional control cohorts [20]-[27]. With the proliferation of digital replicas of humans, there will be an enhanced capacity to forecast the effects of medicine prior to its administration to the patient. Consequently, the improvement of medication usage will be facilitated with the ability to test the most effective drug, dosage, timing, and method of administration in a person's digital counterpart. This approach will effectively minimize the potential harm that a patient may encounter. The utilization of digital twins is expected to enhance the advancement of precision medicine [21] [22] and contribute to the increased implementation of "virtual" or "in silico" clinical trials, hence optimizing the efficiency of the clinical trials domain [23].

The implementation of virtual or in silico clinical trials will have a significant impact on regulatory professionals, as ensuring the integrity of the data will be

come of utmost importance. The process of digitizing regulatory operations will be facilitated by various initiatives, including the adoption of the International Organization for Standardization's (ISO) Identification of Medicinal Products (IDMP) standards. These standards necessitate the management of substance, product, organization, and referential [SPOR] data [24].


The statement is based on the growing inclination towards structured data formats. This inclination facilitates the instantaneous transfer of data to national regulatory agencies through cloud-based systems like Accumulus Synergy. In the forthcoming years, there will be a growing reliance on data flows rather than document flows within the regulatory field. Consequently, regulatory professionals will need to enhance their digital literacy skills to effectively participate to these evolving data processes [25] [26].

## 6. Global Regulatory Harmonization

Considering the progress made in the field of complex pharmaceuticals, regulatory bodies are displaying a growing inclination to collaborate through a range of techniques, including harmonization, convergence, dependence, collaborative review, and work-sharing. The global COVID-19 pandemic has further expedited this trend [27] [28] [29]. Harmonization refers to the procedure of incorporating both national and worldwide standards to enhance the effectiveness and streamline the global development and regulation of pharmaceuticals [30]. One notable illustration involves the incorporation of the International Council for Harmonization [ICH] standards by regulatory bodies at the national level [31].

## 7. Digitalization of Regulatory Affairs

The different regulatory bodies are switching from paper based to eCTD submission. Various authorities have stopped accepting CTD (paper based) submissions. This step has been taken to centralize the process and also to speed up the process of submissions. The roadmap of the change in global regulatory Affairs to adopt digital adoption is mentioned in **Figure 1**. The transition from paper-based



**Figure 1.** Global digital adoption in regulatory Affairs.

to electronic Common Technical Document (eCTD) submission has had a significant impact on regulatory processes globally. The acceptance of eCTD format submissions has led to optimization of resources, increased efficiency, and improved tracking of applications during review [32]. This transition has also ensured that the content of submissions is consistent with global standards [32]. Practical examples of how eCTD submission is being implemented globally can be seen in various countries. For instance, in Japan, the Ministry of Health, Labor, and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) have collaborated to enhance eCTD and e-clinical trials [33]. This initiative aims to support the development of new drugs through the electronic standardization of clinical trials [34]. Similarly, in the United States, the Food and Drug Administration (FDA) has implemented eCTD submission requirements for various types of applications, including new drug applications, biologics license applications, and abbreviated new drug applications [34]. The implementation of eCTD submission has had a positive impact on regulatory processes. Studies have shown that individuals with eCTD experience have been able to shorten their total time to approval and demonstrate cost savings compared to paper submissions [35]. This has been observed across different types of companies, regardless of their size or number of submissions [35]. Furthermore, the use of eCTD has facilitated the review and lifecycle management of electronic submissions, leading to harmonized electronic submission and review initiatives [36]. The organized collection and storage of manufacturing information, including in-process release testing, specification testing, and batch release data, in a structured format within data lakes would enhance the ability to gather and share data to meet regulatory compliance needs [37]. The automation of eCTD compilation facilitates the more effective transfer of data into the current eCTD format for regulatory filings. At present, the process of eCTD creation necessitates human supervision and understanding of the information included within the papers. These documents are often in a portable document format (pdf), which lacks the capability to facilitate automated traceability to the original data sources or enable data mining for enhanced insights [38]. The utilization of structured content and data management systems holds the potential to enhance the efficiency of data management processes, as well as facilitate the creation and dissemination of regulatory documents.

Until now, several organizations have been creating customized internal structured content management systems, specifically for clinical data. However, it is necessary for enterprises and regulatory bodies to adopt shared approaches to facilitate the efficient interchange of data and documents [25] [37] [38]. The ongoing development of initiatives such as Transcelerate's Common Protocol Template and the FDA's Knowledge-Aided Assessment and Structured Application (KASA) is contributing to the standardization of product quality/chemistry-manufacturing-controls (CMC) data. Additionally, the widespread adoption of the ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Prod-

uct Lifecycle Management guideline is also playing a role in promoting the use of more structured formats for both clinical and CMC data packages [37] [38]. The adoption of structured data formats for regulatory information will facilitate regulatory professionals in allocating additional time towards data analysis and the production of insights, specifically pertaining to the benefit-risk assessment of the product [38]. Simultaneously, the implementation of more systematic benefit-risk assessments by National Regulatory Authorities (NRAs) has the potential to enhance worldwide harmonization of benefit-risk assessment and establish a framework that can be integrated into health authorities' benefit-risk algorithms [39].

In conclusion, the transition from paper-based to eCTD submission has brought about significant improvements in regulatory processes globally. The acceptance of eCTD format submissions has optimized resources, increased efficiency, and facilitated tracking of applications during review. Practical examples of eCTD implementation can be seen in countries like Japan and the United States. The impact of eCTD submission has been demonstrated through shorter approval times and cost savings. Overall, the adoption of eCTD has led to harmonized electronic submission and review initiatives, enhancing regulatory processes in the pharmaceutical industry.

## 8. Challenges

There exist several issues pertaining to each of these trends that necessitate addressing, since they have implications for drug research, medical practice, and the responsibilities of regulatory professionals. The primary obstacles associated with the emergence of artificial intelligence (AI) and machine learning (ML) pertain to matters of governance and ethics. Ethical considerations encompass various aspects such as safeguarding human autonomy, well-being, and privacy. It is crucial to ensure transparency and explain ability in the deep learning models employed in artificial intelligence (AI) and machine learning (ML). Additionally, responsible and accountable utilization of these technologies is imperative. Furthermore, promoting inclusivity and equity to mitigate bias and fostering responsive and sustainable AI are essential objectives (40). Governance problems encompass various aspects related to the management of data, particularly in the context of training artificial intelligence and machine learning systems. These concerns involve ensuring that informed permission is appropriately obtained for the use of data in such processes, implementing effective deidentification techniques to preserve individual privacy, establishing protocols for data sharing, management, and control, addressing cybersecurity risks, and determining the assignment of intellectual property rights [40]. Robust governance and ethical frameworks are essential for enhancing trust in the use of AI/ML. Furthermore, firms that depend on these systems must build effective quality assurance and auditing methods. Regulatory professionals must possess a strong level of confidence in effectively communicating and elucidating the intricacies



of these technologies. This is crucial to ensure adherence to government regulations and to facilitate effective collaboration with regulatory bodies during the registration process of AI/ML-based therapeutic devices. Organizations must possess the capability to incorporate these systems into their established benefit-risk decision-making procedures and effectively convey this integration both internally and externally to relevant stakeholders.


The phenomenon of digital disruption presents significant challenges for enterprises in terms of enhancing the skills and knowledge of their workforce through upskilling and reskilling initiatives [41]. The primary factors that will contribute to the effective implementation of digital change management inside businesses are the cultural obstacles that need to be overcome. These include establishing a culture that promotes continuous learning, fostering an agile attitude among employees, and ensuring that all staff members are actively involved in the process of digital transformation.

Organizations are compelled to undertake a comprehensive evaluation of their leadership styles, staff competency profiles necessary for a successful organizational change, and incentives aimed at fostering ongoing professional growth among their personnel. The examination and alteration of entrenched mindsets and infrastructure are necessary to provide adequate assistance to staff members throughout this transitional period. One further difficulty pertains to the escalating rate of change, which has resulted in staff members experiencing burnout and perceiving themselves as unable to engage in further adaptation. The potential consequences and effects resulting from the departure of highly skilled employees who may have difficulties in adapting to new job responsibilities necessitate the establishment of a robust and nurturing work environment. The establishment of a sustainable workforce that can effectively operate in a hybrid working environment necessitates the implementation of robust organizational change management strategies. These strategies are crucial for cultivating an organizational culture that motivates employees to embrace change and enhance their skills to meet the evolving demands of the business [42]. One potential solution to address these challenges is the implementation of a mentorship program, wherein proficient staff members provide guidance and assistance to their less confident counterparts during their transition period. It will be crucial to provide support to staff members in engaging in both internal and external learning opportunities, as this will enable them to enhance their abilities and gain expertise in utilizing new systems and adopting novel approaches to work (Table 1).

## 9. Skills Needed for the Future Regulatory Affairs

The regulatory affairs team will be affected by the advancements in healthcare, medicine, and the pharmaceutical and medical device business. The conventional burden characterized by heavy task-oriented work will undergo transformation through the implementation of digital solutions and automation, necessitating the development of more comprehensive strategic leadership abilities.

**Table 1.** Skills for future readiness for the regulatory affair professionals.

		
Task to Growth Mindset	Team of Teams	Self Learning- Leadership
<ol style="list-style-type: none"> <li>1) Inclusion of external perspectives</li> <li>2) Innovation, creativity, and narrative</li> <li>3) Agile and risk-taking—digitally literate</li> <li>4) Complex thinking and problem-solving</li> </ol>	<ol style="list-style-type: none"> <li>1) Curiosity, connection and collaboration</li> <li>2) Knowledge transfer and adopting innovation—Influence</li> <li>3) Communication</li> </ol>	<ol style="list-style-type: none"> <li>1) Active, life-long learning</li> <li>2) Resilience and optimism—</li> <li>3) Generative leadership</li> </ol>

Hence, it is imperative that regulatory professionals possess the necessary skills, information, and mindset to foster their personal growth and enhance their career trajectories. The contemporary labor landscape is characterized by volatility, uncertainty, complexity, and ambiguity (VUCA). The global pandemic has further exacerbated these characteristics, giving rise to a “new normal” in the world of work [43].

The identification of crucial talents for the future of work has been undertaken by the World Economic Forum. These skills encompass analytical thinking and innovation, active learning, complex problem-solving, critical thinking, and analysis, as well as creativity, originality, and initiative (World Economic Forum, [44]). The future of work necessitates the acquisition of several additional talents. These qualities encompass leadership and social influence, proficiency in utilizing, designing, and monitoring technology, resilience, the capacity to handle stress, adaptability, reasoning, problem-solving, and creativity [45]. According to the Institute for the Future, there are several more abilities that have been highlighted as crucial for the future of work. These talents include sense-making, cross-cultural competency, virtual cooperation, and trans-disciplinarity (Institute for the Future, [44]). The acquisition of these abilities will prove crucial in the endeavor to establish successful jobs within the pharmaceutical and medical technology sector.

Considering the significant influence of digital transformation, it is imperative for regulatory professionals to prioritize the enhancement of their digital literacy competencies. This entails cultivating proficiency in utilizing dashboards and cloud-based platforms for the purpose of visualizing data, comprehending the processes involved in data acquisition, processing, analysis, and predictive utilization, as well as honing statistical data analysis and data mining proficiencies [25]. Furthermore, it is necessary to enhance proficiencies in intricate reasoning and problem-solving, adaptable thinking, agility, effective communication, team-

work, and leadership as well as initiative. Generative leaders, who aspire to improve the world during their tenure, employ a holistic approach by integrating their cognitive abilities, emotional intelligence, and practical skills to maximize their impact. This necessitates a forward-thinking perspective by envisioning and revamping approaches to effectively cater to all parties involved (exemplifying intellectual leadership). It involves cultivating a culture that motivates and empowers individuals to perform at their highest potential (exemplifying emotional leadership). Additionally, it entails implementing strategies and empowering teams to successfully execute plans (exemplifying practical leadership) as mentioned in **Table 1**. The concept of big picture thinking involves incorporating external perspectives into one's decision-making process. The qualities of innovation, creativity, and storytelling are essential elements in fostering novel ideas and effective communication.

One important aspect of being digitally savvy is the ability to demonstrate agility and engage in intelligent risk-taking. Complex reasoning and problem-solving are cognitive processes that include the use of advanced mental abilities to analyse and resolve intricate problems or challenges. These processes need individuals to engage in higher-order thinking, such as critical thinking, logical reasoning, and creative problem-solving. Complex reasoning and problem-solving skills are essential. Secondly, team of teams, the three key elements that are integral to the topic at hand are curiosity, connection, and collaboration. The impact of knowledge transfer and the adoption of innovation Communication is the process of transmitting information, ideas, and thoughts between individuals or groups. It involves the exchange of messages through many channels. Thirdly, when we talk about the self-learning and leadership, three key elements that are integral to the topic at hand are curiosity, connection, and collaboration. Communication is the process of transmitting information, ideas, and thoughts between individuals or groups. It involves the exchange of messages through many channels.

Professionals that actively engage in self-directed learning will possess the ability to adapt to the ongoing changes occurring within the industry, particularly in the field of regulatory affairs. By doing so, they will be able to position themselves effectively for potential growth possibilities in the future.

Regulatory professionals must collaboratively devise a comprehensive strategy for their ongoing professional growth and education in coordination with their supervisors. This should be done after a thorough evaluation of their individual competencies and identification of areas that want improvement. Individuals may opt for a combination of formal schooling, short-term courses, micro credentials, or informal learning activities to enhance their skill set [45]. Engaging in short-term tasks across several domains facilitates the expansion of knowledge, fostering stronger connections and promoting a broader understanding of different perspectives.

In conclusion, it is imperative for regulatory professionals to remain abreast of

pertinent government evaluations that have the potential to affect their respective firms and the sector.

## 10. Conclusions

Around the world, regulatory bodies and organizations must ensure the safety, quality, and efficacy of medicines and medical devices, as well as the harmonization of legislative procedures linked to drug development, monitoring, and assuring compliance with statutory responsibilities. The regulatory affairs profession is poised for an exhilarating future that will be influenced by various variables, with digital disruption playing a prominent role.

The phenomenon of digital disruption is widespread and has significant effects on several domains of work. This influence has been further intensified by the COVID-19 epidemic, as well as the rapid advancements in the complexity and capabilities of machine learning and artificial intelligence algorithms. The future of this profession is influenced by various trends, including the swift progress in scientific comprehension of diseases, which has resulted in the emergence of novel therapeutic approaches for the treatment and potential eradication of some ailments.

The regulatory landscape at a global level has seen significant transformations in recent years, placing increased importance on strategic partnerships, alignment, and integration across national regulatory bodies. This trend is expected to persist in the future. As these aspects commence to have influence on the activities of regulatory professionals, as well as medication development and medical practice, it would be intriguing to examine their repercussions in the forthcoming years. The implementation of these modifications necessitates the enhancement of the skill set possessed by regulatory affairs professionals, as well as a shift from a narrow focus on specific tasks to a broader mindset that embraces growth. In this new paradigm, individuals are encouraged to proactively take charge of their own professional development, exhibit adaptability, and adopt a mindset that emphasizes ongoing learning. By doing so, these professionals can effectively leverage their influence on product development, thereby contributing to the improvement of their respective societies.

## Conflicts of Interest

The authors declare no conflicts of interest regarding the publication of this paper.

## References

- [1] UK Government, Medicines and Healthcare Products Regulatory Agency [MHRA] (2021) Putting Patients First: A New Era for Our Agency. Delivery Plan 2021-2023. <https://www.gov.uk/government/publications/the-medicines-and-healthcare-products-regulatory-agency-delivery-plan-2021-2023>
- [2] Woo, M. (2019) An AI Boost for Clinical Trials. *Nature*, **573**, S100-S102. <https://doi.org/10.1038/d41586-019-02871-3>

- [3] Cecchini, M., Rubin, E.H., Blumenthal, G.M., Ayalew, K., Burris, H.A., Russell Einhorn, M., *et al.* (2019) Challenges with Novel Clinical Trial Designs: Master Protocols. *Clinical Cancer Research*, **25**, 2049-2057. <https://doi.org/10.1158/1078-0432.CCR-18-3544>
- [4] Claro, R.A., Spillman, D., Hotaki, L.T., Shum, M., Mouawad, L.S., Santos, G.M., *et al.* (2020) Project Orbis: Global Collaborative Review Program. *Clinical Cancer Research*, **26**, 6412-6416. <https://doi.org/10.1158/1078-0432.CCR-20-3292>
- [5] Australian Government, Department of Health and Aged Care (2021) Australia Canada-Singapore-Switzerland-United Kingdom (Access) Consortium.
- [6] Government and Regulatory Bodies around the World. <https://Pharmweb.net/pwmirror/pwk/pharmwebk.html>
- [7] Naughtin, C., Hajkowicz, S., Schleiger, E., Bratanova, A., Cameron, A., Zamin, T., *et al.* (2022) Our Future World: Global Megatrends Impacting the Way We Live over Coming Decades. CSIRO, Brisbane.
- [8] Ang, K., Saw, E., He, W., Dong, X. and Ramakrishna, S. (2021) Sustainability Framework for Pharmaceutical Manufacturing (PM): A Review of Research Landscape and Implementation Barriers for Circular Economy Transition. *Journal of Cleaner Production*, **280**, Article ID: 124264. <https://doi.org/10.1016/j.jclepro.2020.124264>
- [9] Socal, M., Sharfstein, J. and Greene, J. (2021) The Pandemic and the Supply Chain: Gaps in Pharmaceutical Production and Distribution. *American Journal of Public Health*, **111**, 635-639. <https://doi.org/10.2105/AJPH.2020.306138>
- [10] K Government (2021) Life Sciences Vision. Build Back Better: Our Plan for Growth.
- [11] MTPConnect (2022) Sector Competitiveness Plan. <https://www.mtpconnect.org.au/reports/SCP>
- [12] Deml, M., Jungo, K., Maessen, M., Martani, A. and Ulyte, A. (2022) Megatrends in Healthcare: Review for the Swiss National Science Foundation's National Research Programme 74 (NRP74) "Smarter Health Care". *Public Health Reviews*, **43**, Article ID: 1604434. <https://doi.org/10.3389/phrs.2022.1604434>
- [13] Jayatunga, M., Xie, W., Ruder, L., Schulze, U. and Meier, C. (2022) AI in Small-Molecule Drug Discovery: A Coming Wave? *Nature Reviews Drug Discovery*, **21**, 175-176. <https://doi.org/10.1038/d41573-022-00025-1>
- [14] Alphabet Inc. (2022) AlphaFold Reveals the Structure of the Protein Universe. <https://www.deepmind.com/blog/alphafold-reveals-the-structure-of-the-protein-universe>
- [15] Pun, F.W., Liu, B.H., Long, X., Leung, H.W., Leung, G.H., Mewborne, Q.T., *et al.* (2022) Identification of Therapeutic Targets for Amyotrophic Lateral Sclerosis Using PandaOmics—An AI-Enabled Biological Target Discovery Platform. *Frontiers in Aging Neuroscience*, **14**, Article ID: 914017. <https://doi.org/10.3389/fnagi.2022.914017>
- [16] Ren, F., Ding, X., Zheng, M., Korzinkin, M., Cai, X., Zhu, W., *et al.* (2022) AlphaFold Accelerates Artificial Intelligence Powered Drug Discovery: Efficient Discovery of a Novel Cyclin-Dependent Kinase 20 (CDK20) Small Molecule Inhibitor. *Chemical Science*, **14**, 1443-1452. <https://doi.org/10.1039/D2SC05709C>
- [17] Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., *et al.* (2021) Applying and Improving AlphaFold at CASP14. *Proteins*, **89**, 1711-1721. <https://doi.org/10.1002/prot.26257>
- [18] National Academies of Sciences, Engineering, and Medicine (2021) Innovations in Pharmaceutical Manufacturing on the Horizon: Technical Challenges, Regulatory

- Issues, and Recommendations. The National Academies Press, Washington DC.
- [19] Smiatek, J., Jung, A. and Bluhmki, E. (2020) Towards a Digital Bioprocess Replica: Computational Approaches in Biopharmaceutical Development and Manufacturing. *Trends in Biotechnology*, **38**, 1141-1153.  
<https://doi.org/10.1016/j.tibtech.2020.05.008>
- [20] GSK (2022) Digital Twin: Using Advanced Technology to Accelerate Vaccine Development.  
<https://www.gsk.com/en-gb/behindthe-science-magazine/digital-twin-using-advanced-technology-to-acceleratevaccine-development>
- [21] Armeni, P., Polat, I., De Rossi, L., Diaferia, L., Meregalli, S. and Gatti, A. (2022) Digital Twins in Healthcare: Is It the Beginning of a New Era of Evidence-Based Medicine? A Critical Review. *Journal of Personalized Medicine*, **12**, 1255.  
<https://doi.org/10.3390/jpm12081255>
- [22] Kamel Boulos, M. and Zhang, P. (2021) Digital Twins: From Personalised Medicine to Precision Public Health. *Journal of Personalized Medicine*, **11**, 745.  
<https://doi.org/10.3390/jpm11080745>
- [23] Sinisi, S., Alimguzhin, V., Mancini, T., Tronci, E. and Leeners, B. (2020) Complete Populations of Virtual Patients for *in Silico* Clinical Trials. *Bioinformatics*, **36**, 5465-5472. <https://doi.org/10.1093/bioinformatics/btaa1026>
- [24] Phillips, V. (2022) The Changing Role of Regulatory Operations. *Regulatory Rapporteur*, **19**, 10-23.
- [25] Macdonald, J., Isom, D., Evans, D. and Page, K. (2021) Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution? *Frontiers in Medicine (Lausanne)*, **8**, Article ID: 660808.  
<https://doi.org/10.3389/fmed.2021.660808>
- [26] Van Belkum, S., Brun, N., Cleve, S., McGovern, P., Lumpkin, M., Schaeffer, P., *et al.* (2022) Artificial Intelligence in Clinical Development and Regulatory Affairs—Preparing for the Future. *Regulatory Rapporteur*, **15**, 17-21.
- [27] National Academies of Sciences, Engineering and Medicine (2020) Regulating Medicines in a Globalized World: The Need for Increased Reliance among Regulators. The National Academies Press, Washington DC.
- [28] Bolislis, W.R., Lucia, M.L., Dolz, F., Mo, R., Nagaoka, M., Rodriguez, H., *et al.* (2021) Regulatory Agilities in the Time of COVID-19: Overview, Trends, and Opportunities. *Clinical Therapeutics*, **43**, 124-139.  
<https://doi.org/10.1016/j.clinthera.2020.11.015>
- [29] Zerhouni, E. and Hamburg, M. (2016) The Need for Global Regulatory Harmonization: A Public Health Imperative. *Science Translational Medicine*, **8**, 338ed6.  
<https://doi.org/10.1126/scitranslmed.aaf1396>
- [30] Lezot, P. (2014) International Cooperation, Convergence and Harmonization of Pharmaceutical Regulations: A Global Perspective. Academic Press, Oxford.
- [31] International Council for Harmonisation (2022) International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Guideline Implementation.  
<https://www.ich.org/page/ich-guideline-implementation>
- [32] O'Brien, J., Lumsden, R., Diehl, D.H. and Macdonald, J. (2020) Building a Better Approach for the Benefit of Patients: 10 Pillars to Strengthen Regulatory Review Systems Globally. *Therapeutic Innovation & Regulatory Science*, **54**, 283-292.  
<https://doi.org/10.1007/s43441-019-00055-9>

- [33] Nordfeld, K. and Strasberger, V. (2006) Creating ECTD Applications. *Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector*, **3**, 140-146. <https://doi.org/10.1057/palgrave.jgm.4940111>
- [34] Nakai, K., Araki, Y., Ebina, D., Watanabe, T., Tanaka, Y. and Toyoshima, S. (2009) Electronic Common Technical Document Implementation in Japan. *Drug Information Journal*, **43**, 395-401. <https://doi.org/10.1177/009286150904300402>
- [35] Suchanek, A. and Ostermann, H. (2012) The Electronic Common Technical Document (ECTD): An International Pro/Con Analysis of the Pharmaceutical Product Electronic Submission Process. *Drug Information Journal*, **46**, 124-139. <https://doi.org/10.1177/0092861511427871>
- [36] Molzon, J.A., Giaquinto, A., Lindström, L., Tominaga, T., Ward, M.A., Doerr, P., Hunt, L.C., *et al.* (2011) The Value and Benefits of the International Conference on Harmonisation to Drug Regulatory Authorities: Advancing Harmonization for Better Public Health. *Clinical Pharmacology & Therapeutics*, **89**, 503-512. <https://doi.org/10.1038/clpt.2011.10>
- [37] Beetham, H. and Sharpe, R. (2013) Rethinking Pedagogy for a Digital Age: Designing for 21st Century Learning. 2nd Edition, Routledge, Oxon. <https://doi.org/10.4324/9780203078952>
- [38] Algorri, M., Cauchon, N. and Abernathy, M. (2020) Transitioning Chemistry, Manufacturing, and Controls Content with a Structured Data Management Solution: Streamlining Regulatory Submissions. *Journal of Pharmaceutical Sciences*, **109**, 1427-1438. <https://doi.org/10.1016/j.xphs.2020.01.020>
- [39] Ahluwalia, K., Abernathy, M.J., Beierle, J., Cauchon, N.S., Cronin, D., Gaiki, S., *et al.* (2022) The Future of CMC Regulatory Submissions: Streamlining Activities Using Structured Content and Data Management. *Journal of Pharmaceutical Sciences*, **111**, 1232-1244. <https://doi.org/10.1016/j.xphs.2021.09.046>
- [40] Chisholm, O., Sharry, P. and Phillips, L. (2022) Multi-Criteria Decision Analysis for Benefit Risk Analysis by National Regulatory Authorities. *Frontiers in Medicine (Lausanne)*, **8**, Article ID: 820335. <https://doi.org/10.3389/fmed.2021.820335>
- [41] World Health Organization (2021) Ethics and Governance of Artificial Intelligence for Health: WHO Guidance. World Health Organization, Geneva.
- [42] Li, L. (2022) Reskilling and Upskilling the Future-Ready Workforce for Industry 4.0 and beyond. *Information Systems Frontiers*, **13**, 1-16. <https://doi.org/10.1007/s10796-022-10308-y>
- [43] Odor, H. (2018) Organizational Change and Development. *European Journal of Business and Management*, **10**, 58-66.
- [44] World Economic Forum (2020) The Future of Jobs Report 2020.
- [45] Institute for the Future (2020) Future Work Skills 2020 Report. <https://legacy.iftf.org/futureworkskills>